Free shipping on all orders over $ 500

Polmacoxib

Cat. No. M21500

All AbMole products are for research use only, cannot be used for human consumption.

Polmacoxib Structure
Synonym:

CG100649

Size Price Availability Quantity
5mg USD 80  USD80 In stock
10mg USD 135  USD135 In stock
25mg USD 270  USD270 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Polmacoxib (CG100649) is a first-in-class, orally active non-steroidal anti-inflammatory compound (NSAID) that acts as a dual inhibitor. It inhibited COX-2 (IC50 ~ 0.1 μg/ml) and carbonic anhydrase. CG100649's interaction with CA in red blood cells provides a new "tissue-specific" transport mechanism designed to deliver sustained levels of the compound to inflamed tissues while maintaining low systemic exposure. Its unique dual COX-2 and CA-binding properties are designed to provide potentially higher safety for cardiovascular, renal and gastrointestinal tissues than conventional NSaids or COX-2 inhibitor drugs. In mouse models, CG100649 inhibited precancerous and malignant colorectal lesions, in part by inhibiting tumor cell proliferation.

Chemical Information
Molecular Weight 361.39
Formula C18H16FNO4S
CAS Number 301692-76-2
Solubility (25°C) DMSO ≥ 200 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Yong-Soon Cho, et al. Clin Ther. Population Pharmacokinetic and Pharmacodynamic Analysis of Polmacoxib in Healthy Volunteers and Patients With Osteoarthritis

[2] In-Gyu Song, et al. Ann Coloproctol. An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient

[3] Claudiu T Supuran. Expert Opin Drug Metab Toxicol. An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors

[4] Myungchul Lee, et al. Clin Orthop Surg. A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis

[5] Hyun Tae Kim, et al. Biochem Biophys Res Commun. Structural insight into the inhibition of carbonic anhydrase by the COX-2-selective inhibitor polmacoxib (CG100649)

Related COX Products
Sudoxicam

Sudoxicam is a reversible and orally active COX antagonist and a non-steroidal anti-inflammatory agent from the enol-carboxamide class.

Metyrosine

Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine significantly inhibits high COX-2 activity. Metyrosine exerts anti-inflammatory and anti-ulcerative effects.

PPOH 

PPOH, a fatty acid derivative, is a selective cyclooxygenase (COX) inhibitor that inhibits arachidonic acid cyclooxygenase activity in renal cortical microsomes.

Tenidap

Tenidap, a non-steroidal anti-inflammatory drug, is a selective COX-1 inhibitor, with IC50 values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively.

COX-2-IN-6 

COX-2-IN-6 is an orally active, gut-restricted and selective cyclooxygenase-2 (COX-2) inhibitor for colorectal Chemoprevention of cancer.

  Catalog
Abmole Inhibitor Catalog




Keywords: Polmacoxib, CG100649 supplier, COX, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.